天德化工(00609.HK)料年度業績扭虧為盈
格隆匯12月27日丨天德化工(00609.HK)公告,根據董事會目前可得的資料及就集團截至2019年11月30日止11個月未經審核綜合管理賬目初步審閲,集團錄得公司擁有人應占未經審核綜合淨利潤約為人民幣1630萬元。
集團預期將由截至2018年12月31日止年度的公司擁有人應占淨虧損約人民幣6100萬元轉變為截至2019年12月31日止的公司擁有人應占淨溢利,唯取決於物業、廠房及設備的最終減值評估。
該改進主要是由於(i)集團實施積極的銷售和營銷策略重獲市場份額並增加銷量,從而增加收入;(ii)對生產費用採取有效成本控制措施和對生產廠房內工作崗位重新定位以精簡工作流程;及(iii)實施有效的採購策略以控制原材料成本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.